心房颤动合并急性冠状动脉综合征患者冠状动脉介入治疗术后抗栓药物应用  

Optimal Antithrombotic Strategic Decision in Patients with Atrial Fibrillation and Acute Coronary Syndrome after Percutaneous Coronary Intervention

作　　者：李京秀[1] 闫述钧[1] 刘史浩 宋兆焱 宋巍 郭龙哲 韩百合 李阳[1] 夏德军 李馨[1] 李学奇[1] 金恩泽[1] 

机构地区：[1]哈尔滨医科大学附属第四医院心血管内科,哈尔滨150001

出　　处：《医学综述》2017年第20期4122-4126,共5页Medical Recapitulate

基　　金：黑龙江省留学归国科学基金(LC2011C10);哈尔滨医科大学第四临床医学院杰出青年基金(HYDSYJQ201504)

摘　　要：心房颤动是心血管内科常见病之一,其发病率与年龄有一定相关性,随着人口老龄化的进程,心房颤动的发生率亦逐年递增。心房颤动患者自身多存在血栓或出血倾向,具有较高的致残及致死率。随着临床研究的不断深入与细化,接受冠状动脉介入治疗的患者中心房颤动患者占有较高比例。因此,针对心房颤动并接受冠状动脉支架治疗的患者如何进行出血与栓塞风险的评估,权衡利弊,规范化、个体化、精准地选择抗栓药物,是心血管内科临床研究的热点。Atrial fibrillation is one of the common diseases of cardiovascular medicine,the incidence and age of which have a certain relevance,and with the aging process of population,the incidence of atrial fibrillation is increasing year by year.There is a significant thromboembolism and bleeding tendency in patients with atrial fibrillation,so these patients often have a higher morbidity and mortality rate.With the deepening and refinement of the clinical research,there is a higher proportion of patients receiving coronary artery intervention among patients with atrial fibrillation.Therefore,for patients with atrial fibrillation receiving coronary artery stent treatment,how to assess the risk of bleeding and embolism,weigh the pros and cons,standardized,individual,accurate selection of antithrombotic drugs,are the hot spots of the clinical research of cardiovascular medicine.

关 键 词：心房颤动 经皮冠状动脉支架置入术 华法林 氯吡格雷 

分 类 号：R541.4[医药卫生—心血管疾病]